Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
WIGRETTES vs ERGOLOID MESYLATES
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicotine replacement therapy: binds to nicotinic acetylcholine receptors in the brain, releasing dopamine and providing nicotine to reduce withdrawal symptoms and cravings.
Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.
Smoking cessation therapy,Relief of nicotine withdrawal symptoms
Treatment of age-related cognitive decline,Dementia (unlabeled use)
1 mg sublingually as needed for smoking cessation, up to 4 times daily. Maximum daily dose: 4 mg.
Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in moderate renal impairment.
2-4 hours for parent drug; clinical significance: drug accumulation unlikely with normal dosing intervals.
Primarily hepatic via CYP2A6 and CYP2B6; also metabolized by aldehyde oxidase and N-glucuronidation.
Hepatic metabolism via CYP3A4 primarily; extensive first-pass effect.
Renal excretion of unchanged drug accounts for 50-60% of the dose; biliary/fecal elimination accounts for 20-30%; remainder metabolized.
Primarily fecal (biliary) as metabolites and unchanged drug; renal elimination accounts for less than 10% of the dose.
90-95% bound to albumin and alpha-1-acid glycoprotein.
Approximately 90% bound to albumin.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive tissue distribution.
1.5-2 L/kg, indicating extensive tissue distribution.
Oral bioavailability is 60-80%; intramuscular bioavailability is 90-100%.
Oral: less than 10% due to extensive first-pass metabolism.
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
Not studied; no specific recommendations. Caution advised in severe renal impairment (GFR <30 m L/min).
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 1 mg maximum twice daily. Child-Pugh Class C: Avoid use (not recommended).
Contraindicated in Child-Pugh class C (severe hepatic impairment). Use with caution in Child-Pugh class B; reduce dose by 50%.
Not approved for patients under 18 years of age.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment; monitor for adverse effects due to potential age-related decreased renal function.
Initiate at 1 mg twice daily; titrate slowly. Monitor for orthostatic hypotension and cognitive effects.
None
No FDA black box warning.
Risk of nicotine toxicity if used while smoking; caution in cardiovascular disease, hypertension, diabetes, hyperthyroidism, pheochromocytoma; may cause allergic reactions including angioedema; pregnancy category D.
Use with caution in patients with hypotension, bradycardia, or history of psychosis; may cause orthostatic hypotension; monitor for signs of ergotism.
Hypersensitivity to nicotine or any component; nonsmokers; immediate post-myocardial infarction period; life-threatening arrhythmias; severe or worsening angina pectoris.
Hypersensitivity to ergot alkaloids; severe hypotension; acute or chronic psychosis; concurrent use with potent CYP3A4 inhibitors (e.g., macrolide antibiotics, azole antifungals).
No known food interactions. Avoid concurrent use of retinoid creams or other exfoliating agents that may increase skin sensitivity.
Avoid grapefruit juice as it may increase drug levels. Limit caffeine intake as it may exacerbate vasoconstrictive effects. Maintain adequate hydration.
WIGRETTES contains nicotine, which is a known teratogen. First trimester exposure is associated with increased risk of spontaneous abortion, preterm birth, and low birth weight. Second and third trimester exposure can lead to reduced fetal growth, placental complications (e.g., abruption), and potential neurobehavioral effects. The risk is dose-dependent and compounded by maternal smoking.
Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. Second/Third trimester: Contraindicated due to oxytocic effects causing uterine hypertonicity, placental hypoperfusion, and fetal distress. Use only if benefit outweighs risk for life-threatening conditions.
Nicotine is excreted into breast milk with a milk-to-plasma ratio of approximately 2.9. Concentrations can exceed maternal serum levels. Nursing infants are at risk for nicotine absorption leading to irritability, sleep disturbances, and reduced milk intake. Breastfeeding is generally discouraged during nicotine replacement therapy; if used, timing of patches should minimize infant exposure (e.g., remove at night).
Excreted into breast milk; M/P ratio unknown. May suppress prolactin and reduce milk production. Potential for ergotism in neonates (vomiting, diarrhea, convulsions). Contraindicated during breastfeeding.
Pregnancy increases nicotine clearance by approximately 60%, potentially reducing efficacy of standard doses. Higher doses of nicotine replacement therapy may be required to achieve therapeutic effect and prevent withdrawal. However, safety of high-dose NRT in pregnancy is not established. Dose should be individualized based on maternal smoking history and withdrawal symptoms.
No established safe dose in pregnancy. Avoid use. If absolutely necessary, lowest effective dose and shortest duration, but no specific pharmacokinetic data available to guide adjustments.
Wigrettes are wax-based hair removal products containing depilatory agents like calcium thioglycolate. For scalp use only; avoid contact with eyes and broken skin. Perform a patch test 24 hours prior to first use. Do not use on irritated or sunburned skin. Overuse may cause chemical burns or allergic contact dermatitis. Duration of application time is critical: typically 5-10 minutes, do not exceed 15 minutes. Remove with a wooden spatula in direction of hair growth. Neutralize residue with water or mild soap.
Ergoloid mesylates are a mixture of dihydrogenated ergot alkaloids historically used for dementia, though efficacy is unproven. Avoid in patients with psychosis, severe bradycardia, or recent MI. Monitor for ergotism symptoms (vasospasm, ischemia). Not recommended due to lack of evidence.
Read all directions before use.,Do a patch test on a small area of skin 24 hours before use.,Apply only to clean, dry scalp hair; not for eyebrows, eyelashes, or body hair.,Avoid contact with eyes, nose, and mouth. If contact occurs, rinse with plenty of water.,Do not use on sunburned, broken, or irritated skin.,Set a timer; do not leave on longer than directed (usually 5-10 minutes, max 15 minutes).,Remove product gently with the provided spatula in the direction of hair growth.,Rinse scalp thoroughly with water after removal; do not use soap immediately if irritation occurs.,Do not use more than once every 72 hours.,Store in a cool, dry place away from children.
Take exactly as prescribed; do not double doses if missed.,Report signs of ergotism: cold/blue fingers/toes, muscle pain, tingling or numbness.,Avoid smoking and caffeine as they may worsen vasoconstriction.,May cause dizziness or fainting; avoid driving until you know how the drug affects you.,Do not use with other ergot alkaloids or triptans.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about WIGRETTES vs ERGOLOID MESYLATES, answered by our medical review team.
WIGRETTES is a Ergot Alkaloid that works by Nicotine replacement therapy: binds to nicotinic acetylcholine receptors in the brain, releasing dopamine and providing nicotine to reduce withdrawal symptoms and cravings.. ERGOLOID MESYLATES is a Ergot Alkaloid that works by Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between WIGRETTES and ERGOLOID MESYLATES depend on the specific clinical indication. These are both Ergot Alkaloid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of WIGRETTES is: 1 mg sublingually as needed for smoking cessation, up to 4 times daily. Maximum daily dose: 4 mg.. The standard adult dose of ERGOLOID MESYLATES is: Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between WIGRETTES and ERGOLOID MESYLATES in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. WIGRETTES is classified as Category C. WIGRETTES contains nicotine, which is a known teratogen. First trimester exposure is associated with increased risk of spontaneous abortion, preterm birth, and low birth weight. Se. ERGOLOID MESYLATES is classified as Category A/B. Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.